Nitric oxide and phosphodiesterase-5 inhibitors: possible treatments for COVID-19 in diabetes


  • Martin B Whyte University of Surrey King's College Hospital NHS Foundation Trust
  • Prash Vas King's College Hospital NHS Foundation Trust
  • Philip A Kelly King's College Hospital NHS Foundation Trust
  • Christian Heiss University of Surrey
  • Michael D Feher University of Oxford



type 2 diabetes, pulmonary microcirculation, COVID-19, nitric oxide, phosphodiesterase-5 inhibitor

Author Biographies

Martin B Whyte, University of Surrey King's College Hospital NHS Foundation Trust

Consultant Diabetologist

Clinical Senior Lecturer in Metabolic Medicine

Prash Vas, King's College Hospital NHS Foundation Trust

Consultant Diabetologist

Philip A Kelly, King's College Hospital NHS Foundation Trust

Consultant Physician

Christian Heiss, University of Surrey

Professor of Cardiovascular Medicine

Michael D Feher, University of Oxford

Honorary Professor Diabetes


Chen Y, Gong X, Wang L, Guo J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv 2020 (Published Online First 30 March 2020). 2020

NHS England. Type 1 and type 2 diabetes and COVID-19 related mortality in England. Available from: (accessed 28 June 2020).

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239–42.

Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metabolism 2020 (Published Online First 1 May 2020). doi:

Cariou B, Hadjadj S, Wargny M, et al, for the CORONADO Investigators. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia 2020;63(8):1500–15.

Stehouwer CDA. Microvascular dysfunction and hyperglycemia: a vicious cycle with widespread consequences. Diabetes 2018;67(9):1729–41.

Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395(10234):1417–18.

Lax SF, Skok P, Kessler HH, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series Ann Intern Med 2020 (Published Online First 14 May 2020).

Brownrigg JR, Hughes CO, Burleigh D, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016; 4(7):588–97.

Davis WA, Knuiman M, Kendall P, et al. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004;27(3):752–7.

Chance WW, Rhee C, Yilmaz C, et al. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care 2008;31(8):1596–601.

Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26(5):948–68.

Mori H, Okubo M, Okamura M, et al. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Intern Med 1992;31(2):189–93.

Sandler M, Bunn AE, Stewart RI. Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus. Am Rev Respir Dis 1987;135(1):223–9.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054–62.

Ozdemir B, Yazici A. Could the decrease in the endothelial nitric oxide (NO) production and NO bioavailability be the crucial cause of COVID-19 related deaths? Med Hypotheses 2020;144:109970.

Velmurugan S, Gan JM, Rathod KS, et al. Dietary nitrate improves vascular function in patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 2016;103(1):25–38.

Heiss C, Keen CL, Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J 2010;31(21):2583–92.

Balzer J, Rassaf T, Heiss C, et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients: a double-masked, randomized, controlled trial. J Am Coll Cardiol 2008; 51(22):2141–9.

Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag 2006;2(4):411–22.

Chen L, Liu P, Gao H, et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 2004;39(10):1531–5.

Akerstrom S, Mousavi-Jazi M, Klingstrom J, et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005;79(3):1966–9. Nitric oxide gas inhalation therapy for mild/moderate COVID-19 (NoCovid). NCT04305457. 2020. Available from: (accessed 19 May 2020). Nitric oxide gas inhalation in severe acute respiratory syndrome in COVID-19 (NOSARSCOVID). NCT04306393. 2020. Available from: (accessed 19 May 2020).

McGonagle D, O'Donnell JS, Sharif K, Emery P, Bridgewood C. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2020;2(7):437–45.

Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8(6):546–50.